#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Dementia Alzheimer's type Colorectal cancer Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Adenocarcinoma gastric Small cell lung cancer recurrent Rosai-Dorfman syndrome Hypoparathyroidism Erythema Congenital generalised lipodystrophy Bladder cancer Nodal marginal zone B-cell lymphoma Ductal adenocarcinoma of pancreas Congenital megacolon Rett syndrome Anti-neutrophil cytoplasmic antibody positive vasculitis Mantle cell lymphoma recurrent Acute graft versus host disease in liver Chronic lymphocytic leukaemia More trials…

    Learn about Rare Diseases

    Primary biliary cholangitis – Trials in Disease Sjogren’s syndrome – Trials in Disease Rhabdoid tumour – Life with Disease Methylmalonic acidaemia – Trials in Disease Mantle cell lymphoma refractory Hairy cell leukaemia recurrent – Trials in Disease Breast angiosarcoma metastatic – Treatment Mastocytosis Angiosarcoma – Basic Information Gaucher’s disease type III – Basic Information More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    IBUZATRELVIR Cyclophosphamide Mk-1167 Sym023 Cetuximab Cimetidine Azd4831 Pasireotide Diaspartate APROTININ Degarelix DISODIUM PHOSPHATE Azd3470 Gad20-209-Fsp-A2 Moxifloxacin Hydrochloride Sotatercept PALAZESTRANT Busulfan Human Apotransferrin Abc-24F-116 Alisertib Sodium More therapies…

    Learn about Your Condition

    Testicular germ cell cancer Colorectal adenoma Hodgkin's disease refractory HER2 negative breast cancer Malabsorption Staphylococcal infection Genitourinary tract neoplasm Combined immunodeficiency Netherton's syndrome Decreased appetite Small for dates baby Astrocytoma malignant Autoimmune uveitis Trisomy 21 Haemoptysis More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Metastases to central nervous system

  • Study on the Safety and Effectiveness of Repotrectinib for Patients with ROS1-Positive Non-Small Cell Lung Cancer and Active Brain Metastasis

    Recruiting

    2 1 1
    Investigated Diseases:
    • Metastases to central nervous system
    • Non-small cell lung cancer
    Investigated Drugs:
    • Repotrectinib
    Austria Germany Spain

  • Evaluation of Bevacizumab in Patients with Brain Radionecrosis After Radiation Treatment for Brain Metastases

    Recruiting

    3 1 1
    Investigated Diseases:
    • Metastases to central nervous system
    Investigated Drugs:
    • Bevacizumab
    • Sodium Chloride
    • Prednisolone
    France

  • Study of AZD9574 and Temozolomide for Patients with Advanced Solid Tumors, Including Breast, Ovarian, Pancreatic, and Prostate Cancers

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Metastases to biliary tract
    • Metastases to central nervous system
    • Metastatic glioma
    Investigated Drugs:
    • 6-Fluoro-5-[4-[(5-Fluoro-2-Methyl-3-Oxo-4H-Quinoxalin-6-Yl)Methyl]Piperazin-1-Yl]-N-Methylpyridine-2-Carboxamide
    • [11C]Az14193391
    • Trastuzumab Deruxtecan
    Spain Sweden

  • Study of Ipilimumab and Nivolumab with or without Radiotherapy for Patients with Melanoma Brain Metastases

    Not yet recruiting

    2 1 1 1
    Investigated Drugs:
    • Ipilimumab
    • Nivolumab
    Italy

  • Study on 68Ga-NOTA-Anti-HER2 VHH1 for Cancer Patients with Brain Metastasis

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Metastases to central nervous system
    Investigated Drugs:
    • 68Ganota-Anti-Her2 Vhh1
    Belgium

  • Study on Nivolumab, Ipilimumab, and Bevacizumab for Patients with Non-Small Cell Lung Cancer Spread to the Brain

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Metastases to central nervous system
    • Non-small cell lung cancer
    Investigated Drugs:
    • Ipilimumab
    • Bevacizumab
    • Nivolumab
    Germany
1 2
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!